Cyramza generated revenues of $196 million, which reflected ~23% growth on a YoY basis and 5% growth on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Cyramza reported revenues of $69.5 million and $126.5 million, respectively, compared to $67.0 million and $92.0 million in 3Q16.
http://marketrealist.com/2017/12/eli-lillys-cyramza-performed/
How Has Eli Lilly’s Cyramza Performed